Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Daren Lin"'
Autor:
Qingyuan Zhang, Jingxuan Wang, Quchang Ouyang, Xiaojia Wang, Jingfen Wang, Lu Gan, Daren Lin, Zhong Ouyang, Ting Xu, Yilan Liu, Summer Xia
Publikováno v:
Cancer Research. 83:PD18-08
Background: 1. The 3-drug combination therapy, trastuzumab, pertuzumab, and taxane chemotherapy is one of the standard treatment options for the first-line treatment of HER2-positive recurrent/metastatic breast cancer. 2. KN026 is a novel bispecific
Autor:
Derong Xie, Won Seog Kim, Yuan Zhu, Xin Du, Ting Liu, Junxin Wu, Tao Wu, Pingyong Yi, Yanming Deng, Xiangyuan Wu, Gang Wu, Xiaoyan Ke, Huangming Hong, Jie Jin, Ye Guo, Wei-Li Zhao, Kangsheng Gu, Fanyi Meng, Mingzhi Zhang, Zhigang Peng, Jinghua Wang, Jun Zhu, Tongyu Lin, Daren Lin, Chaoyong Liang, Qing Liu, He Huang, Juan Li, Soon Thye Lim, Yexiong Li
Publikováno v:
Leukemia
Autor:
Lin Xiao, Wenhai Huang, Daren Lin, Bin Wang, Ting Cao, Yanming Huang, Xingxing Chai, Xiangmeng Chen, Ronggang Li, Wansheng Long, Qiong Chen, Chen Jiarong, Minyan Wu, Jincheng Zeng, Lin Zhichao, Wenguang Pang, Wenjie Lu, Fangyong Lei, Zhihui Wang, Shasha Chen, Xin Zhang, Aibin Liu, Jun Li, Yan Zheng, Meigong Zhong, Dong Ren, Zhuming Lu, Mingzhu Zheng
Publikováno v:
Cancer letters. 482
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death due to its early recurrence and widespread metastatic potential. Accumulating studies have reported that dysregulation of circadian rhythms-associated regulators is impli
Autor:
Shijie Mai, Shiyue Zhang, Qing Zhou, Wenjing Wang, Weiguang Gu, Peng Zhang, Daren Lin, WenFan Fu
Publikováno v:
Cancer Research. 79:1691-1691
Background: Immune checkpoint inhibitors have provided remarkable antitumor effects in non-small cell lung cancer (NSCLC), while their efficacy in patients harboring driver mutations is still controversial and the correlation between driver gene muta
Autor:
Jamie A. Seabrook, Daren Lin, Doreen Matsui, Susan M. King, Michael J. Rieder, Yaron Finkelstein
Publikováno v:
Pharmacoepidemiology and Drug Safety. 20:1246-1252
Purpose To assess the impact of perceived palatability of antiretroviral drugs on adherence to therapy of children infected by human immunodeficiency virus and on prescribing patterns by their caring physicians. Methods Design: Two arms—retrospecti
Autor:
Siyang Wang, Li Zhang, Wei Min Zhang, Ning Li, Hong-Yu Zhang, Wei Dong, Daren Lin, Jun Jia, Xiaolong Cao, Cong Xue, Shaodong Hong, Jiewen Peng, Weineng Feng
Publikováno v:
Scientific Reports
There is no consensus on the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. This randomized, open-label, multicenter study aimed to explore whether dose-escalation of g
Publikováno v:
CJEM. 17(5)
ObjectiveElderly patients often present to the emergency department (ED) with non-specific complaints. Previous studies indicate that such patients are at greater risk for life-threatening illnesses than similarly aged patients with specific complain
Autor:
Daren Lin, Andrew Worster
Publikováno v:
CJEM. 15(6)
Objectives:To identify factors known prior to triage that might have predicted hospital admission for patients triaged by the Canadian Triage Acuity Scale (CTAS) as level 5 (CTAS 5, nonurgent) and to determine whether inappropriate triage occurred in
Autor:
Andrew Worster, Heather Patterson, Layli Sanaee, Kamyar Kahnamoui, Julien Payrastre, Daren Lin, Suneel Upadhye, Rob Clayden
Publikováno v:
CJEM. 14(6)
Objective:To derive and internally validate a clinical decision rule that will rule out major thoracic injury in adult blunt trauma patients, reducing the unnecessary use of chest computed tomographic (CT) scans.Methods:Data were retrospectively obta
Publikováno v:
Zhongguo fei ai za zhi = Chinese journal of lung cancer. 9(5)
Paclitaxel plus cisplatin is an effective regimen in the treatment of non-small cell lung cancer (NSCLC), but it has severe adverse toxicities. The aim of this clinical trial is to evaluate the effect and safety of paclitaxel plus oxaliplatin compare